| Date | Title | Description |
| 06.10.2025 | RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01 | RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company developing novel therapies derived from neo... |
| 02.05.2025 | RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell & Exosome Therapy Manufacturing | RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in... |
| 02.05.2024 | BioSolution Designs and RoosterBio Announce Collaboration on Genetically Modified MSCs for Biotherapeutic Development | RoosterBio
Together, BSD and RoosterBio deliver an end-to-end solution for the engineering and development of cell- and exosome-based therapeutics.
FREDERICK, Md., May 2, 2024 /PRNewswire-PRWeb/ -- BioSolution Designs (BSD), a biotechnology... |
| 02.05.2024 | BioSolution Designs and RoosterBio Announce Collaboration on Genetically Modified MSCs for Biotherapeutic Development | FREDERICK, MARYLAND, UNITED STATES, May 2, 2024 /EINPresswire.com/ -- BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for multigenic gene and cell therapies, today announced its ongoing strategic... |
| 26.04.2023 | NanoFCM Partners with RoosterBio as an Approved Service Provider for Exosome Analysis | The in-depth knowledge and expertise in EV characterization provided by RoosterBio will allow new and existing EV platforms to thrive in this exciting field.”
— Ben Peacock, Head of Research for NanoFCM Co., Ltd.
FREDERICK, MD, USA, April 2... |
| 13.03.2023 | RoosterBio and Repligen Collaborate to Advance Scalable Exosome Bioprocessing | We are thrilled to partner with Repligen to accelerate our customers’ path to the clinic and enable successful commercialization of innovative exosome therapies.”
— Tim Kelly, Chief Executive Officer of RoosterBio
FREDERICK, MD, UNITED STAT... |
| 13.03.2023 | RoosterBio and Repligen Collaborate to Advance Scalable Exosome Bioprocessing | "We are thrilled to partner with Repligen to accelerate our customers’ path to the clinic and enable successful commercialization of innovative exosome therapies.” - Tim Kelly, Chief Executive Officer, RoosterBio
FREDERICK, Md. (PRWEB)... |
| 25.10.2022 | FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to Enable GMP Manufacturing of Cell and Exosome Therapies | "Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to partner with FUJIFILM Diosynth Biotechnologies to translate our MSC and exosome technologies into advanced therapy product... |
| 24.10.2022 | FUJIFILM Diosynth Biotechnologies & RoosterBio Collaborate to Enable GMP Manufacturing of Cell & Exosome Therapies | This collaboration will enable us to become a fully integrated cell therapy CDMO partner to our biopharma customers.”
— Gerry Farrell, chief operating officer, FUJIFILM Diosynth Biotechnologies
COLLEGE STATION, TEXAS, UNITED STATES, October... |
| 30.08.2022 | RoosterBio and MBL Beijing Biotech Partner to Accelerate Advanced Therapy Manufacturing in China | “RoosterBio’s engineered media products are creating transformative impact for cell and exosome therapy developers all over the world." - Tim Kelly, CEO, RoosterBio
FREDERICK, Md. (PRWEB) August 30, 2022
RoosterBio, Inc., a leading sup... |
| 18.08.2022 | RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies | “AGC Biologics has an outstanding track record of success in the manufacture of clinical and commercial advanced therapies and an ever-expanding global network to meet the needs of our customers.” - Tim Kelly, CEO, RoosterBio
FREDERICK, Md.... |
| 16.08.2022 | RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies | RoosterBio and AGC Biologics Announce Collaboration
New partnership delivers clinically proven products and manufacturing processes for advanced therapies
SEATTLE, WASHINGTON, UNITED STATES, August 16, 2022 /EINPresswire.com/ -- AGC Biologi... |
| 26.04.2022 | ShiftBio partners with RoosterBio to accelerate development of a novel genetically engineered exosome, SBI-102 for rare diseases and cancer | "The opportunity to forge a true collaboration and create this kind of impact to accelerate advanced therapies to patients is what drives our entire organization.” - Tim Kelly, CEO, RoosterBio
FREDERICK, Md. (PRWEB) April 26, 2022
Shif... |
| 26.04.2022 | ShiftBio Partners with RoosterBio to Accelerate Development of a Novel Genetically Engineered Exosome, SBI-102 | RoosterBio’s MSC-derived exosome bioprocess technology platform enables accelerated development of ShiftBio’s lead therapeutic candidate.
We are thrilled to partner with ShiftBio, a global innovator in the field of exosomes, to advance thei... |
| 04.04.2022 | Cell and Gene Therapy Pioneer Robert Preti Joins RoosterBio Board of Directors | “Bob is truly a pioneer in the cell and gene therapy industry and has played a pivotal role in advancing our field while delivering needed therapies to thousands of patients." - Tim Kelly, CEO, RoosterBio
FREDERICK, Md. (PRWEB) April 0... |
| 20.01.2022 | Univercells Technologies Partners with RoosterBio to Advance Scalable and Continuous Exosomes Manufacture | "We are proud to partner with RoosterBio to demonstrate how purposefully designed technologies such as the scale-X bioreactor portfolio can enable the rapid delivery of reliable and affordable regenerative therapies." - Mathias Ga... |
| 05.10.2021 | RoosterBio Names Life Science Industry Leader, Timothy M. Kelly, Ph.D., as New Chief Executive Officer | "What sets Tim apart is his deep technical knowledge in cell and gene therapy technologies and the specialized manufacturing needs required by these unique therapies.” - Jon A. Rowley, PhD, founder and chief product officer, RoosterBio... |
| 20.05.2021 | RoosterBio Releases RoosterGEM™, Cell and Gene Therapy’s First Complete Transduction Medium | RoosterGEM™ Built with cGMP-compatible processes, RoosterGEM represents a breakthrough in practical transduction efficiency. - Jon Rowley, Founder and Chief Product Officer of RoosterBio
FREDERICK, Md. (PRWEB) May 20, 2021
RoosterBio Inc., ... |
| 11.03.2021 | RoosterBio Inc. Announces Winners of 2020 hMSC Development Grants | We are very pleased to support hMSC-based methods and applications in Genetic Engineering by enabling a rapid and efficient path to generate key cellular raw materials and scale up manufacturing, leading to shortened timelines on research a... |
| 14.01.2021 | RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing | This collaboration is well-positioned to accomplish the clinical scale requirements of regenerative medicine product developers while laying foundation for true commercial scale manufacturing. - RoosterBio CEO Margot Connor
FREDERICK, Md. (... |
| 16.12.2020 | RoosterBio launches next generation EV collection media as part of a complete hMSC-EV production system | RoosterBio Inc RoosterCollect EV Pro is a step change in our customer-focused hMSC EV solutions. Increasing bioproduction efficiency and economy of scale are critical to rapidly advance this field. - RoosterBio Founder and Chief Product Off... |
| 02.12.2020 | RoosterBio Collaborates with Sartorius to Expand Cell and Gene Therapy Manufacturing Platform Technology into South Korea | RoosterBio Inc We believe the talented team at Sartorius is uniquely suited to provide our mutual customers with scalable hMSC systems to expedite their cell-based therapeutic programs. - Margot Connor, CEO of RoosterBio
FREDERICK, Md. (PRW... |
| 12.09.2019 | RoosterBio Raises $21.5 Million And Appoints Daniella Kranjac To The Board | RoosterBio, a company that is simplifying human mesenchymal stem/stromal cell (hMSC) biomanufacturing, announced it has raised $21.5 million.
RoosterBio — a company that is radically simplifying human mesenchymal stem/stromal cell (hMSC) bi... |
| 11.09.2019 | RoosterBio Raises $6.5M; Closes $21.5M Series B Funding | RoosterBio Inc, a Frederick, MD-based company developing tools to simplify human mesenchymal stem/stromal cell (hMSC) biomanufacturing, raised $6.5m in the final tranche of its Series B raise.
The company had announced its first round close... |
| 07.08.2019 | Daily funding roundup - August 7th, 2019 | EnjoyHQ raised $2M; Eager Alpha closed $2.4M; LUCA Biologics landed $2.8M; Crosschq secured $4.1M
EnjoyHQ: EnjoyHQ is the easiest way to search, organize and share all your customer feedback and user research in one place. EnjoyHQ has raise... |
| 07.08.2019 | Frederick-based RoosterBio raises $15M Series B | Frederick-based RoosterBio raised more than $15 million in a Series B funding round as the cell manufacturing technology company looks to grow its team.
The funding was led by Dynamik Capital, with participation from new and existing invest... |
| 06.08.2019 | RoosterBio Raises $15M Series B |
FREDERICK, MD, RoosterBio today announced it has raised in excess of $15 million in an initial Series B financing round.
>> Click here for more funding data on RoosterBio
>> To export RoosterBio funding data to PDF and Excel... |
| 06.08.2019 | Dynamk Capital Leads $15M Series B for RoosterBio | RoosterBio Inc, disrupting the market by radically simplifying human mesenchymal stem/stromal cell (hMSC) biomanufacturing, today announced it has raised in excess of $15 million in an initial Series B financing round led by Dynamk Capital.... |
| 06.08.2019 | RoosterBio Raises $15 Million in Series B Round Led by Dynamk Capital | FREDERICK, MD and NEW YORK, NY – August 6, 2019 – RoosterBio Inc, disrupting the market by radically simplifying human mesenchymal stem/stromal cell (hMSC) biomanufacturing, today announced it has raised in excess of $15 million in an initi... |
| 06.08.2019 | RoosterBio Raises $15M in Initial Series B Round | RoosterBio, Inc., a Frederick, MD-based human mesenchymal stem/stromal cell (hMSC) biomanufacturing company, raised in excess of $15m in an initial Series B financing.
The round was led by Dynamk Capital, with participation from existing an... |
| 06.08.2019 | RoosterBio Raises $15 Million in Initial Series B | RoosterBio Inc, disrupting the market by radically simplifying human mesenchymal stem/stromal cell (hMSC) biomanufacturing, today announced it has raised in excess of $15 million in an initial Series B financing round led by Dynamk Capital.... |
| 27.02.2017 | RoosterBio Raises Over $5.1 Million | RoosterBio Inc. raised almost $5.2 million in equity and option, according to a filing Monday with the Securities and Exchange Commission.
RoosterBio filed a Form D signed by CEO Margot Connor, founder and Chief Technical Officer Jon Rowley... |
| 27.02.2017 | RoosterBio Raises Over $5.1 Million | RoosterBio Inc. raised almost $5.2 million in equity and option, according to a filing Monday with the Securities and Exchange Commission.
RoosterBio filed a Form D signed by CEO Margot Connor, founder and Chief Technical Officer Jon Rowley... |
| 25.02.2014 | RoosterBio Raises over $250K in Seed Funding | RoosterBio Inc., a Frederick, MD-based biotech startup, raised over $250K in seed funding.
Backers were not revealed.
Led by Chief Executive Officer Dr. Jon Rowley and Chief Operating Officer, Dr. Uplaksh Kumar, RoosterBio is a biotech star... |
| 22.01.2014 | CoFoundersLab raises $155K in debt funding [Startup Roundup] | Have news for the Startup Roundup? Get in touch.who’s getting funded?
CoFoundersLab, based in Rockville, Md., has raised $155,000 in debt, according to SEC filings. The startup organizes Meetups in Baltimore city and elsewhere as a way for ... |
